Core Viewpoint - Mirxes has signed a memorandum of understanding with Watson Bio to collaborate in molecular diagnostics and vaccine development, aiming to expand into ASEAN and global markets [1] Group 1: Company Developments - Mirxes' stock rose nearly 8% in early trading, currently up 2.48% at HKD 53.8, with a trading volume of HKD 18.2942 million [1] - The partnership with Watson Bio signifies a strategic collaboration between a leading precision diagnostics company and a top vaccine developer, establishing a solid foundation for an RNA-based preventive and precision medical platform [1] Group 2: Product Approval and Market Impact - In October, Mirxes' core product GASTROClear received approval from the National Medical Products Administration (NMPA) in China, becoming the world's first and only approved molecular diagnostic IVD product for gastric cancer screening [1] - This milestone represents a commercial breakthrough for the company, transitioning from "0 to 1," and is expected to lead to a revaluation of the company's worth [1] - The approval allows Mirxes to enter the vast gastric cancer screening market in China, serving as a significant catalyst for short-term performance [1]

Core Insights - Mirxes-B (02629) experienced a nearly 8% increase in early trading, currently up 2.48% at 53.8 HKD with a trading volume of 18.29 million HKD [1] Company Developments - On November 18, Mirxes announced a formal memorandum of understanding with Watson Bio (300142.SZ) to collaborate in the fields of molecular diagnostics and vaccine development, aiming to expand in the ASEAN and global markets [1] - This partnership signifies a strategic alignment between a leading precision diagnostics company and a top vaccine development firm, laying a solid foundation for a prevention and precision medicine platform centered around RNA [1] Product Milestones - In October, Mirxes' core product GASTROClear received approval from the National Medical Products Administration (NMPA) in China, becoming the world's first and currently the only approved molecular diagnostic IVD product for gastric cancer screening [1] - This milestone represents a significant commercial breakthrough for the company, transitioning from "0 to 1," and introduces a new valuation logic for the firm [1] - The approval allows the company to officially enter the vast gastric cancer screening market in China, serving as a crucial catalyst for short-term performance [1]